Role of fundus fluorescein angiography and optical coherence tomography in diabetic maculopathy: A clinical study. by Suganya, N
1 
Dissertation on 
THE ROLE OF FUNDUS FLUORESCEIN ANGIOGRAPHY 
AND OPTICAL COHERENCE TOMOGRAPHY IN DIABETIC 
MACULOPATHY – A CLINICAL STUDY 
 
 
Submitted in partial fulfillment of requirements of 
 
M.S. OPHTHALMOLOGY 
BRANCH – III 
 
 
REGIONAL INSTITUTE OF OPHTHALMOLOGY 
MADRAS MEDICAL COLLEGE 
CHENNAI- 600 003 
 
 
 
 
 
 
 
 
 
 
THE TAMILNADU 
DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
APRIL 2012 
2 
CERTIFICATE 
 
This is to certify that this dissertation entitled “THE ROLE OF 
FUNDUS FLUORESCEIN ANGIOGRAPHY AND OPTICAL 
COHERENCE TOMOGRAPHY IN DIABETIC MACULOPATHY – A 
CLINICAL STUDY” is a bonafide record of the research work done by 
Dr.N.SUGANYA., Post graduate in Regional Institute of Ophthalmology, 
Madras Medical College and Research Institute, Government General 
Hospital,Chennai-03, in partial fulfillment of the regulations laid down by 
The TamilNadu Dr.M.G.R. Medical University for the award of M.S. 
Ophthalmology Branch III, under my guidance and supervision during the 
academic years 2009-2012.  
 
 
Prof. Dr. A.SULAIMAN M.S., D.O 
H.O.D of Retina Services 
RIOGOH, Chennai- 600008 
 
Prof. Dr.K.VASANTHA M.S , FRCS 
Director and Superintendent,        
Regional Institute of Ophthalmology 
Madras Medical College  
Chennai – 600 008       
 
 
 
 
Dr. V. KANAGASABAI, MD, Ph.D 
Dean, 
Madras Medical College & 
Govt. General Hospital, 
Chennai-600 003 
 
 
3 
 
REGIONAL INSTITUTE OF OPHTHALMOLOGY  
MADRAS MEDICAL COLLEGE  
CHENNAI- 600 003 
 
                
DECLARATION BY THE CANDIDATE 
 
 
I hereby declare that this dissertation entitled  “THE ROLE OF 
FUNDUS FLUORESCEIN ANGIOGRAPHY AND OPTICAL 
COHERENCE TOMOGRAPHY IN DIABETIC MACULOPATHY – A 
CLINICAL STUDY” is a bonafide and genuine research work carried out by 
me under the guidance  of Prof. Dr. Jayasungathi, M.S.D.O.,  
Prof. Dr.Sulaiman, M.S.,D.O., Prof. Dr.Revathi M.S.,D.O., Professors, 
Department of Retina Services, Regional Institute of Ophthalmology &  
Government Ophthalmic hospital, Chennai – 600008.                                  
 
 
 
 
 
 
 
Date:                                                                                   Dr.Suganya.N 
 
Place: 
 
 
 
 
4 
ACKNOWLEDGEMENT 
I express my sincere thanks and gratitude to  
Prof. Dr. V. KANAGASABAI M.D., Ph.D., Dean, Madras Medical 
College for permitting me to conduct this study.. 
I have great pleasure in thanking professor                                                
Dr. K. VASANTHA, M.S.,F.R.C.S., Director and Superintendent RIO 
– GOH, Madras Medical College, Chennai, for her valuable advice in 
preparing this dissertation.  
I express my profound gratitude to Prof. Dr. Jayasuganthi M.S. 
D.O., Prof. Dr.Sulaiman, M.S.,D.O., Prof. Dr.Revathi M.S.,D.O., my 
unit chiefs and for their valuable guidance and constant support at every 
stage throughout the period of this study.  
I am very grateful to my unit assistants Dr. Rajasekar M.S.,  
Dr. Balaji M.S., Dr. Sivagami M.S.,  for rendering their valuable 
advice and guidance for the study.  
I wish to express my sincere thanks to all the professors, assistant 
professors and all my colleagues who had helped me in bringing out this 
study.   
Finally, I am indebted to all the patients for their sincere co-
operation for the completion of this study.  
 
 
5 
CONTENTS 
S. NO. TITLE PAGE 
NO. 
 PART -  I  
1  INTRODUCTION                                                                                           3
2 ANATOMY OF MACULA 4 
3 CLINICAL ASSOCIATIONS AND RISK 
FACTORS    
8 
4 PATHOPHYSIOLOGY OF DIABETIC 
MACULAR EDEMA   
10 
5 CLINICAL PRESENTATION 12 
6 FUNDUS FLUORESENCE PATTERNS OF 
DIABETIC MACULAR EDEMA 
18 
7 OPTICAL COHERENCE TOMOGRAPHY 
PATTERNS OF     DIABETIC   MACULAR 
EDEMA 
24 
8 MANAGEMENT 30 
 PART-II  
9 AIM OF THE STUDY 39 
10 INCLUSION AND EXCLUSION CRITERIA 40 
11 MATERIALS AND METHODS 40 
12 OBSERVATION AND RESULTS 43 
13 DISCUSSION 61 
14 CONCLUSION 63 
 
PART – III 
 
15 BIBLIOGRAPHY 69 
16 PROFORMA  71 
17 MASTER CHART 74 
18 KEY TO MASTER CHART   75 
 
6 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
PART ONE 
 
 
 
 
 
       
 
 
 
 
 
 
7 
 
                                       ABBREVIATIONS 
 
DR  - Diabetic retinopathy 
NPDR - Non proliferative diabetic retinopathy 
PDR  - Proliferative diabetic retinopathy   
FFA  - Fundus Fluorescein Angiography 
OCT  - Optical Coherence Tomography     
WESDR - The Wisconsin Epidemiologic Study of Diabetic 
Retinopathy      
DCCT - The Diabetes Control and Complication Trial 
CSME - Clinically significant macular edema 
ETDRS - The Early Treatment Diabetic Retinopathy Study 
VEGF - Vascular endothelial growth factor 
 
 
 
 
 
 
 
 
 
 
 
 
8 
INTRODUCTION 
Diabetic retinopathy (DR) is a microvascular  complication of 
both type I and type II diabetes mellitus (DM) has  become one of the 
leading causes of blindness world wide (Wilkinson 1988)1. It is a 
preventable blindness. DR is due to microangiopathy affecting the pre 
capillary arterioles, capillaries and venules. 
Macular edema is an important and complex component of  Non 
proliferative diabetic retinopathy (NPDR) and Proliferative diabetic 
retinopathy (PDR)  and is the major cause of impaired vision. This study 
focusses on the role of Fundus Fluorescein Angiography (FFA) and 
Optical Coherence Tomography (OCT) in  diabetic macular edema and 
its management.  
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ANATOMY OF THE MACULA 
Anatomically the macula is defined as that portion of the  
posterior retina that contains xanthophyllic pigment and two or more  
layers of ganglion cells. The macular region is a specialised area of the   
central retina with a diameter of 5.5 mm and is centered approximately 
4 mm temporal to and 0.8 mm inferior to the centre of the optic disc. 
This area can be divided into  several regions: the foveola, fovea, 
parafoveal area and perifoveal region. The central portion of macula 
contains the fovea  and the foveola is a small depression in the internal 
surface of retina measuring about 0.35 mm in diameter. The fovea is 
located about 4mm temporal and  0.8mm inferior to the centre of optic 
disc. 
The thickness of retina in the fovea is 0.13mm  elsewhere it is 
0.37 mm.The only photoreceptors in the fovea are cones. The inner 
nuclear, inner plexiform,ganglionic cell layer, nerve fibre layers are 
absent in the fovea. The entire vascular supply to the fovea is via the 
choriocapillaries. The maximal thickness of the retina is at the foveal 
margin is 0.55 mm and minimal thickness is at the umbo 0.13 mm. 
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At the macula ganglion cells are more numerous than anywhere 
else in the retina. The outer plexiform layer has a reticular structure but 
at the macula it is called the Henle ‘s layer. The fibres run at first 
vertically, then obliquely near the macula and finally parallel to the 
surface. This layer is thickest at the macula and absent at the fovea. 
There are no rods in the fovea. 2,3 
PARAMETERS OF MACULA 
The diameter of fovea  - 1.5 mm   
The diameter of parafovea - 2.5 mm 
The diameter of perifovea   - 1.5mm  
PARAFOVEA:    
It is a central annular zone which contain the largest number of 
nerve cells in the entire retina. The thickness of  the photoreceptor layer 
in this portion of retina is 40 -45 microns. 
PERIFOVEA: 
The perifoveal retina is situated beyond the parafoveal area . 
There are 12  cones per each 100 microns in the perifoveal central 
retina. 
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UMBO 
It is a tiny depression in the very centre of the foveola which 
corresponds  to the foveal reflex, loss of which may be an early sign of 
damage. 
BLOOD RETINAL BARRIER: 
The outer blood retinal barrier is formed by the  Zona Occludens  
between retinal pigment epithelial (RPE) cells.The inner blood retinal 
barrier is formed by the tight junctions between retinal capillary 
endothelial cells. 
VASCULAR SUPPLY 
 The outer one third of the retina are supplied by the 
choriocapillaries. The inner twothird ‘s of the retina are supplied by the  
central retinal artery and veins.The inner capillary network is located in 
the ganglion cell layer and the outer in the inner nuclear layer. Capillary 
free zones are present around arterioles (periarteriolar capillary – free 
zone and at the fovea (Foveal avascular zone ).4 
 Retinal capillaries are devoid of smooth muscle  and elastic 
tissue and their walls consist of the following:  
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1. Endothelial cells form a single layer on basement membrane and are 
linked by tight junctions that form the inner blood retinal barrier. 
2. Pericytes lie external to the endothelial cells and have multiple 
pseudopodial processes that envelop the capillary. They have 
contractile properties and are thought to participate in autoreulation 
of microvascular circulation. 
HISTOLOGY  
Based on light microscopic findings the retina is said to be 
composed of ten layers.These from outside to inside are: 
1. The pigmented epithelium 
2. The rods and cones 
3. The external limiting membrane 
4. The outer nuclear layer 
5. The outer plexiform layer 
6. The inner nuclear layer  
7. The inner plexiform layer 
8. The ganlionic cell layer 
9. The nerve fibre layer 
10. The internal limiting membrane 
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EPIDEMIOLOGY 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR)5 is a study on the progression of diabetic retinopathy.The 
duration of diabetes was directly associated with an increased 
prevalence of diabetic retinopathy in people with type 1 and type 2 
diabetes.After 20 yrs of  diabetes, nearly 99% of patients with type 1 
and 60% with type 2 had diabetic retinopathy. 
It is reported that 3% eyes with mild NPDR, 38% with moderate 
to severe NPDR, and 71% eyes with PDR develop Diabetic macular 
edema( DME). The incidence increases with advancing  retinopathy. 
CLINICAL ASSOCIATIONS AND RISK FACTORS 
Diabetic macular edema(DME) severity is associated with  
1. Diabetic retinopathy severity level 
2. Duration of diabetes  mellitus : Retinopathy in young patient with 
Type I DM   does not develop for atleast 3-5 yrs after the onset of the 
disease. In type II DM it is difficult to determine the  duration for the 
development of DR. In patients diagnosed before the age of 30 years, 
the incidence of DR  after 10 years is 50% and after 30 years it is 90%. 
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DR rarely develops within 5 years of the onset  of diabetes or  before 
puberty, but about 5% of type 2 diabetics have DR at presentation. 
3. Glycemic control : The Diabetes Control and Complication 
Trial(DCCT)6 hyperglycemia causes breakdown of the blood retinal  
barrier by three major mechanisms : increased paracellular permeability 
of  vascular endothelium, loss of endothelial cell integrity due to cell 
destruction, and increased transcellular transport through the 
endothelium. Type 1 diabetics appear to obtain greater benefit from tight 
control than those with type 2. Raised HbA1c is associated with an 
increased risk of proliferative disease. 
4. Hypertension : Increased blood pressure increases the risk of  
progression of diabetic retinopathy. Tight control appears to be 
particularly beneficial in type 2 diabetics with maculopathy.7,8 
5. Dyslipedemia 
6. Nephropathy : If severe is associated with worsening of DR. 
Conversely, treatment of renal disease may be associated with 
improvement of retinopathy and a better response to photocoagulation. 
7. Fluid retention  
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8. Pregnancy promotes the progression of DR. Predictating factors 
include  poor pre pregnancy control of diabetes, too rapid control during 
the early stages of pregnancy, and the development of pre eclampsia and 
fluid imbalance. 
9. Intraocular surgery 
10. Uveitis 
11. Panretinal photocoagulation 
12. Anemia induced hypoxia causes the development of 
microanuerysms and other retinopathy changes. 
13. Genetic factors : There has been found an increased risk of PDR 
in subjects with HLA (Human leucocyte antigen) DR4 and DR5  
phenotype. 
14. Ocular factors : Glaucoma reduced the severity and prevalence  of 
DR. 
PATHOPHYSIOLOGY 
There are structural, rheological and biochemical factors that 
contribute to the development of DR 
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I. Structural changes 
1. Capillary basement membrane thickening 
2. Loss of microvascular intramural pericytes 
3. Loss of endothelial cells 
4. Endothelial cell dysfunction 
II. Rheological changes 
1. Platelet abnormalities like increased platelet adhesiveness, 
increased platelet aggregation, decreased platelet survival. 
2. Red blood cell abnormalities like decreased deformability, 
increased rouleaux formation. 
3. Incresed fibrinogen, alpha 2 macrogobulin and haptaglobulin 
III. Biological changes 
1. Prolonged hyperglycemia : Several sugars bind non enzymatically 
to protein forming advanced glycation end products which are 
long lived and play a causal mechanism for the diabetic 
complications. 
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2. Sorbitol pathway: 
Sorbitol formed from glucose by Aldose reductase is converted 
slowly to fructose by sorbitol dehydrogenase.Since the later reaction is 
slow sorbitol builds up to toxic concentration leading to endothelial 
damage. 
3. Increased level of Diacyl glycerol and Protein kinase C which 
causes decreased retinal blood flow. 
4. Vascular Endothelial Growth Factor is a potent permeability 
agent responsible for DME. 
CLINICAL PRESENTATION: 
Patients with DME present with wide range of visual symptoms 
depening on the degree to which fovea is involved. Patients experience 
graual progressive vision loss, loss of colour vision, poor night vision, 
poor dark light adaptation. 
Clinically DME has the following features 
a.  Thickening of macula 
b.  Blurring of the underlying choroidal vascular pattern 
c.  Loss of foveolar light reflex when foveola is involved 
d.  Cystoid spaces 
e.  Lipid exudation from the leaking microanuerysms in the form of 
ring known as circinate retinopathy.  
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CLASSIFICATION 
It is divded into two subtypes Focal and diffuse macular edema. 
Focal macular edema 
            Areas of focal leakage from microanuerysms and dilated 
capillary segments characterize focal macular edema. These areas of 
focal retinal thickness are delineated from the adjacent healthy retina by 
a complete or a partial ring of hard exudates 
Diffuse Macular Edema 
Diffuse macular edema results from the breakdown of blood 
retinal barrier with leakage from microanuerysms and dilated capillary 
bed throughout the posterior retina. It has a tendency to be bilaterally 
symmetrical. They may disappear spontaneously at the same time in 
both eyes even without laser treatment only to reappear later. Systemic 
factors like cardiovascular, renal diseases, systemic hypertension, or pre 
eclampsia may be associated with exacerbation and amelioration of 
diffuse macular edema. 
The Early Treatment Diabetic Retinopathy Study(ETDRS)9  
criteria for clinically significant macular edema(CSME) 
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1. Thickening of the retina < 500 microns from the centre of the 
macula. 
2. Hard exudates with thickening of the adjacent retina located 500 
microns from the centre of macula 
3. A zone of retinal thickening ,1 disc area larger in size located 1 
disc diameter from centre of macula. 
A simpler classification named International Clinical Diabetic 
Macular edema severity scale classified DME as :  
Diabetic macular edema absent: No retinal thickening or hard 
exudates in the posterior pole. 
Diabetic macular edema present: Some retinal thickening or hard 
exudates in the posterior pole. 
Mild Diabetic macular edema: Retinal thickening or hard exudates in 
the posterior pole, but distant from the centre of macula. 
Moderate Diabetic macular edema: Retinal thickening or hard 
exudates approaching the centre of macula but not involving the centre. 
Severe diabetic macular edema: Retinal thickening or hard exudates 
involving the centre of macula. 
20 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 FOCAL EDEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 DIFFUSE EDEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3 ISCHEMIC EDEMA 
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CLINICAL EVALUATION 
 
1. Visual acuity 
Vision loss depends on involvement of the macula. 
2. Colour vision 
Colour vision is documented by Fransworth Munsell 100 hue test. 
The  commenest defect is blue yellow.In diabetes the sensitivity of blue 
cones  are depressed. 
3. Fields 
Field charting by Tangent screen reveals scotomas corresponding 
to the areas of involvement in the fundus. 
4. Indirect ophthalmoscopy   
This technique allows the entire view of the entire retina. 
5. Slit lamp biomicroscopy 
6. Direct ophthalmoscopy 
This method allows a detailed examination of the fundus with 
high magnification. 
7. Threshold Amsler grid charting 
This is useful in determining the central visual field. 
22 
8. Photostress test 
After images and central scotomas persist after a long time. This 
explained the prolonged re-adaptation times in photostress testing the 
affected eye. 
9. Electrophysiology 
i. Electoretinography :  Abnormalities of the oscillatory potential in 
the ascending limb of b wave and delay in implicit time occurs as 
the macular edema progresses. 
ii.  Electrooculography : Abnormal Arden ‘s ratio will be seen in 
DME 
iii. Visually evoked potential : The VER shows reduction in 
amplitude with no change in latency. 
10. Fundus fluorescein angiography 
FFA is done for the diagnosis, documentation, identification of 
leakage  pattern, decision on treatment and the follow up. 
11. OCT 
This is a valuable tool to diagnose, document, ascertain the 
macular  thickness, decide about treatment and for the follow up. 
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FUNDUS FLUORESCEIN ANGIOGRAPHY  
PRINCIPLES: 
FFA is a tool for studying retinal vasculature. In 1910 the two 
medical students Harold Novotny & David Alvis produced the first 
human FFA. Fluorescein was chemcically related to phenolphthalein & 
in alkaline solution forms sodium fluorescein.It is a water soluble, 
orange red crystalline hydrocarbon. When injected into the body 80% is 
bound to the serum proteins and 20% remains unbound and is referred 
to as free fluorescein. Usual dose is 3ml of 20% in adults and 0.04ml/kg 
of 20% in children. 
The retinal capillary endothelial cells are joined  by special 
junctional complexes which make them impermeable to fluorescein and 
leakage from the retinal circulation is pathological. Major choroidal 
vessels are impermeable to both bound and free fluorescein but 
choriocapillaries are extremely permeable. 
PHASES OF THE ANGIOGRAM: 
1. Pre arterial phase or choroidal phase, during which the choroidal 
circulation is filling, but no dye has reached the retinal arteries. 
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2. Arterial phase , which follows one second after the pre arterial phase 
and extends from the first appearance of the dye in the arteries until 
the entire circulation has been filled. 
3. Arterio Venous(AV) phase or the capillary phase which is 
characterised by complete filling of the arteries and capillaries with 
the appearance of early lamellar flow in the veins. 
4. Venous phase which is subdivided according to the extent of venous 
filling and arterial emptying into early, mid, and late stages. 
5. Elimination phase 
TECHNIQUE: 
Fluorescein, usually 5 ml of a 10% or in eyes with opaque media, 
3ml of 25% solution is injected intravenously ino the antecubital vein 
over a few  seconds images are taken at approximately 1 second 
intervals, 5-25 seconds after injection. Late photographs are taken after 
10 minutes and occasionly 20 minutes if leakage is anticipated. 
PATTERNS OF FLUORESCNCE 
1. Hypofluoresence 
Vascular filling defects and blocked fluorescence 
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2.  Hyperfluorescence 
Leakage, staining, pooling, transmission defect. 
3. Autofluorescence 
It is the appearance of fluorescence without dye injection due to 
normally fluorescent structures like drusen and lipofuscin. 
4. Pseudofluorescence 
It is due to mismatch of the filters in which filter fails to block 
unwanted light. 
ADVERSE EFFECTS: 
Discoloration of skin  and urine, nausea, vomiting,, flushing of 
the skin, itching, and excessive sneezing. Serious  but rare problems 
include syncope, laryngeal oedema, bronchospasm and anaphylactic 
shock. 
DISADVANTAGES 
1.  Cannot be performed in hazy media 
2.  Cannot detect lesions under preretinal / subretinal hemorrhage. 
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CONTRAINDICATIONS 
History of reaction to the dye 
Severe renal or liver dysfunction 
FFA CLASSIFICATION OF DME: 
Focal Edema: 
AV phase shows multiple hyperfluorescent points caused by 
microanuerysms bordering the areas of capillary non perfusion. Late 
phase shows increased fuzziness around the micoanuerysm due to 
leakage of the dye. 
Diffuse Edema 
Mid AV phase shows leakage of the dye from the dilated 
capillaries throughout the macula.It is not associated with hard exudates. 
FFA shows early spotty hyperfluorescence of microaneurysm and late 
diffuse hyperfluorescence due to leakage, and may be associated with a 
flower petal pattern if CME is present. Mostly bilaterally symmetrical. 
They may disappear spontaneously at same time in both eyes even 
without laser only to reappear spontaneously. The treatment is grid laser 
photocoagulation to areas of retinal thickening. 
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Ischemic type: 
Retinal capillary nonperfusion is a feature commonly associated 
with progressive NPDR. Microanuerysms tend to cluster at the margins 
of capillary nonperfusion. Closure of retinal arterioles may result in a 
large  area of capillary nonperfusion and progressive ischemia. 
Clinically the macula is normal. FFA shows enlargement of the foveal 
avascular zone greater than 1000µm in diameter. There does not appear 
to be a direct correlation between the level of visual acuity and the 
severity of ischemia.  
It has the following features in FFA 
1. Enlargement of Foveal Avascular Zone (FAZ)  
2. Irreularities of FAZ 
3. Capillary budding into FAZ 
4. Widening of intercapillary space and capillary dropout in 
perifoveal area. 
Treatment is not appropriate in most cases. 
Mixed type: 
Shows features of both  diffuse type of macular edema. and 
ischemia.10, 11, 12, 13 
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Fig.4 FOCAL TYPE   Fig.5 DIFFUE TYPE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 ISCHEMIC TYPE  Fig.7 MIXED TYPE WITH   
GRID LASER MARKS 
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OCT 
 
It provides a high resolution, cross sectional images of the macula 
and allows the measurement of foveal thickness. It also helped in 
determining the vitreo retinal relationship at the macula. OCT is 
superior to FFA in detecting cystoid changes. It captures reflected light 
from retinal structures to create a cross  sectional image of the retina 
with an axial resolution of 15 microns. 
 
PRINCIPLE: 
 
It utilises interferometry and low coherence light in the infrared 
range  (843 nm) to achieve high resolution(about OCT 1 & 2 & about 7 
-8  microns for OCT 3), cross sectional imaging of the eye. An optical 
beam  from a light source which emits short optical pulses or short 
coherence  length light is directed into two beams, one is reflected and 
the other is transmitted. 
 
Advantages to document the clinical efficacy of treatment compared  
 
to conventional FFA: 
 
1. The 2 dimensional cross sectional OCT Scan allows detailed 
examination of macular anatomy distinguishing  intraretinal, 
subretinal  and cystoid fluid accumulation 
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2. The false colour image gives topographic image of the  central fovea 
and perpendicular macular thickness. 
3. The measurements are reliable, reproducible and observer 
independent. 
 
TECHNIQUE: 
 
Following papillary dilatation 6 radial scans are centered on the 
fovea.The retinal architecture is first displayed as a 2 dimensional 
image.  
The retinal mapping program is employed to process the areas 
between 2  neighbouring scans in the periphery & determine the mean 
values of all 6 scans in the macula. 
 
OCT SCAN PROTOCOLS IN MACULA : 
 
1. Line scan 
2. Radial scan 
3. Macular thickness map 
4. Fast macular thickness map 
5. Raster lines 
6. Repeat scan 
 
ANALYSIS PROTOCOL: 
 
1. Retinal thickness 
2. Retinal map 
3. Retinal thickness/Volume 
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INTERPRETATION: 
  
Pathology categorised either as hyperreflective or hyporeflective 
lesion 
 
Hyper reflective lesions 
 
a. Hard exudates 
 
b. Blood 
 
c. Scars 
 
Hypo reflective lesions 
 
 In the outermost ring than in the central zone. 
 
    a.Serous fluid 
 
    b. Hypo pigmented lesions of RPE 
 
 
The OCT patterns in DME  are 
 
1.Sponge like retinal edema: 
 
Thickening of the retina without definite cystic spaces. It is 
mostly confined to the outer plexiform and outer nuclear layers  due to 
back scattering from intra retinal fluid. 
2. Cystoid macular edema: 
Cystoid cavities are hyporeflective spaces of various sizes mainly 
located in the outer retina.In long standing cases  they fuse to form large 
cyst. 
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3. Serous retinal detachment: 
Hypo reflective space under the fovea which may disappear 
spontaneously following laser. 
 
4. Tractional macular edema: 
Foveo vitreal traction causes detachment of fovea.It is an 
indication for Pars Plana Vitrectomy. 
5. Taut Posterior Hyaloid Membrane: 
It may cause recalcitrant macular edema with foveal  detachment. 14, 15 
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Fig.8 SPONGY EDEMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9 CYSTOID EDEMA 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10 SPONGY WITH SEROUS RD 
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Fig.11 VITREOMACULAR TRACTION 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.12 TAUT POSTERIOR HYALOID 
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LIMITATIONS AND PIT FALLS: 
Retinal thickness in each zone is calculated as the average values 
measured on the portion of axis passing through that zone. Therefore 
there are fewer points per surface unit in the outermost ring than in the 
innermost ring therefore more values are extrapolated. 
MANAGEMENT 
Treatment strategies for DME encompasses life style modification 
exercise, smoking cessation, better control of blood sugar, blood 
pressure, blood lipids and body mass index. 
PREVENTION AND CONTROL 
Diabetes mellitus has multifactorial origin control of the 
metabolic abnormalities in diabetes has a major impact on the 
development and progression of diabetic microvascular complications. 
Diabetes Control  and Complication Trial(DCCT) and the united 
kingdom prospective diabetes sudy (UKPDS)16 have shown that optimal 
metabolic control could reduce the incidence and progression of DR. 
Multifactorial control of various risk factors such as HbA1c, blood 
pressure, lipid  profile, anemia, 24 hrs proteinuria, before laser 
photocoagulation led to the reduction in macular edema on OCT. The 
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recommended values for HbA1c,blood pressure, and LDL cholesterol 
are <7 percent, <130/80 mmHg, and <100 mg/dl, respectively. 
LASER THERAPHY FOR DME: 
The goal of macular photocoagulation  is to limit vascular leakage 
through a series of focal laser burns at leaking microanuerysms or grid 
laser burns in regions of diffuse breakdown of the blood retinal barrier. 
The ETDRS compared outcomes in eyes assigned to either deferral of 
macular laser photocoagulation or immediate treatment for CSME. 
The ETDRS used focal  laser photocoagulation for the treatment 
of DME. Results of the treatment  with laser reduced the risk of 
moderate  visual loss(defined as doubling of the visual angle eg. drop of 
3 or more lines in Snellen s equivalent or a drop of 15 or more  letters on 
ETDRS visual acuity chart ), increased the chance of visual  
improvement and was associated with only a minor loss of visual field.17 
TREATABLE LESIONS 
1. Focal leaks > 500 microns from macular centre causing 
thickening or hard exudates. 
2. Focal leaks within 300-500 microns from macular centre thought 
to   be causing thickening or hard exudates. 
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3. Areas of diffuse leakage from microanuerysms and capillary 
leakage 
4. Avascular zones other than Foveal Avascular Zone ,not treated 
previously. 
Modified ETDRS Focal/Grid laser photocoagulation of DME 
i. Lesions closer than 500µm from the fovea should not be                
treated. 
ii. Excessive intense  and excessive density laser burns should be 
avoided 
iii. Intraretinal or preretinal hemorrhages should not be treated                                      
iv. Consider treating large (>40µm) microanuerysms that appear to 
the principal causes of leakage focally to the ETDRS end point of 
colour change(either whitening or darkening). 
TECHNIQUE OF FOCAL LASER 
Focal refers to direct treatment of all leaking microanuerysms in 
the edematous retina between 500-3000 microns from the centre of the 
macula with a spot size of 50-100 microns and exposure time of 0.1 
second. 
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TECHNIQUE OF GRID LASER 
The grid laser is used primarily for areas of diffuse leakage with 
no  identical focal areas of leakage. It consists of light intensity burns 
 50 -100 microns in diameter, producing a grid of equally spaced burns, 
more than one burn width apart.. 
LASER TYPES 
Most frequently used wavelength are 514nm(the green component 
of  the Argon Blue/Green laser) &810nm(from the infrared diode laser). 
The Argon blue green laser should not be used for the treatment of  
microanuerysms that are very close to the central area. This is because 
the blue light is absorbed by xanthophylls pigment overlying parafoveal 
area, this can cause nerve fibre layer damage and parafoveal scotoma. 
SIDE EFFECTS AND COMPLICATIONS 
• Paracentral scotoma 
• Transient increased edema/decreased vision 
• Choroidal neovascularisation 
• Sub retinal fibrosis 
• Photocoagulation scar expansion 
• Inadvertent foveolar burns.18, 19, 20 
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MEDICAL MANAGEMENT OF DME 
INTRAVITREAL STEROIDS 
The rationale for the use of steroids to treat DME is compelling. 
The  molecular biology of diabetic vascular change  includes 
leukostasis, endothelial decompensation and increased levels of 
proinflammatory cytokines. Steroids may be useful to treat diabetic 
macular edema because of anti-inflammatory effects which include 
decreased inflammatory cell activation, adhesion and growth factor 
signalling. Steroids have a direct effect on maturation of  
interendothelial  cell  junction and improved barrier properties. The 
duration of drug in the vitreous cavity approximates the duration of  
clinical effect(2-3 months for 4mg injection of triamcinolone). 
In patients with refractory DME intravitreal  steroids have been  
used. Intravitreal triamcinolone 4mg / 0.1 ml alone or in combination 
with laser therapy, has been has been the subject of multiple 
investigations of therapy for DME. Patients with a cystoid component to 
their ME respond better. Visual decline are often observed  4 – 6 months 
after injection. Repeated therapy is often limited by side  effects. Side 
effects include intraocular pressure elevation, acceleration of  cataract, 
endophthalmitis, retinal detachment.21 
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INTRAVITREAL ANTI VASCULAR ENDOTHELIAL GROWTH 
 FACTORS (VEGF)  
Angiogenesis formation is central to the  pathology of 
proliferative diabetic retinopathy and is stimulated by factors such as 
VEGF in response to retinal ischemia. VEGF may induce inflammation 
by inducing intracellular adhesion molecule –1 (ICAM-1) expression 
and leucocyte adhesion. Anti VEGF agents restore the normal 
permeability of the blood retinal barrier.   
Bevacizumab is a full length, recombinant, humanized,  
monoclonal antibody directed against VEGF. In cases of diffuse DME 
that failed other treatments, intravitreal injection of bevacizumab 
1.25mg in 0.05 ml was associated with improved vision and decreased 
retinal thickness 12 weeks after the first injection. However the effect is 
transient and the injection needs to be repeated  at 4-6 weeks interval. 
Pegatinib sodium (Macugen) 0.3 mg/0.05 ml 3 injections at  6 
week intervals and were followed for 36 weeks. Pegatinib is a anti 
VEGF pegylated aptamer, that specifically binds and neutralises 
VEGF165, has been tried in recalcitrant ME. 
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              Ranibizumab(Lucentis) is an intravitreally injected, 
recombinant, humanized, monoclonal antibody fragment designed to  
actively bind and inhibit all isoforms of VEGF.Complications include 
endophthalmitis, cataract, vitreous hemorrhage.injection site bleeding 
and pain.22 
PHARMACOTHERAPY 
1. Aldose reductase inhibitors – Sorbinil,Ponalrestat,Tolrestat 
Aldose reductase enzyme facilitates the conversion of glucose to 
sorbitol.They slow the development of diabetic retinopathy. 
2. Advanced Glycation End Products inhibitors  
3. Protein kinase inhibitors – Ruboxistaurin Protein kinase C ß is 
specifically upregulated in hyperglycemia in tissues like vascular 
endothelial cells, and mediates some of the myriad biochemical 
disturbances. Ruboxistaurin  decreased abnormal vascular 
permeability and also inhibited  angiogenesis in nondiabetic 
retinal ischemia model. 
4. Antioxidants : The formation of reactive oxygen species(ROS) 
had been known to cause the development of diabetic 
complications. Diabetes may cause  ROS production through 
glucose auto oxidation, increased flux  through the polyol 
pathway, and increase in protein glycation. 
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 Inhibition of superoxide production can effectively block sorbitol 
accumulation, AGE formation, and PKC activation.  
SURGICAL MANAGEMENT OF DME 
Pars plana vitrectomy and detachment of posterior hyaloid is 
useful in treating DME when there is evidence of posterior hyaloidal 
traction and taut posterior hyaloid. The Diabetic Retinopathy 
Vitrectomy Study (DRVS) was established to explore the possibilities 
and  outcomes of vitrectomy in selected eyes. The results suggest that 
early vitrectomy should be considered in eyes with recurrent vitreous  
hemmorhage. Additional indications include traction of the disc,  
peripapillary retina or macula that distorts  these structures  and lead  to 
reduction in vision, opaque fibrous proliferation in front of the retina  
and extensive pre retinal hemorrhage. 
Vitrectomy with or without membrane peeling of posterior 
hyaloid membrane may be beneficial for the treatment of DME in eyes 
that are resistant to laser photocoagulation.23 
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AIM OF THE STUDY 
i. To study the prevalence of diabetic maculopathy in relation to 
age, gender, duration of diabetes mellitus. 
ii. To classify diabetic maculopathy using FFA & OCT  
iii. To treat diabetic maculopathy according to FFA & OCT 
classification. 
iv. To monitor the response to treatment with OCT. 
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MATERIALS AND METHODS 
This study was conducted in Regional Institute of Ophthalmology And 
Government Ophthalmic Hospital, Egmore, Chennai from November 2009 to 
November 2011 for a period of 24 months. 
INCLUSION CRITERIA:  
All patients with clinically significant macular edema and with 
central subfield macular thickness more than 200 microns. 
EXCLUSION CRITERIA: 
i. History of severe systemic disease/steroids 
ii. Uncontrolled Diabetes mellitus/Hypertension 
iii. Any condition affecting follow up. 
iv. History of associated  glaucoma/ocular hypertension 
v. History or evidence of ongoing uveitis 
vi. Advanced diabetic eye disease 
All the patients were taken a brief history and subjected to detailed  systemic 
and ophthalmic examination. Anterior segment examination with slit lamp 
biomicroscope and posterior segment examination using 90 D, binocular indirect 
ophthalmoscope. Fundus photograph was also taken for documentation. Fundus 
fluorescein angiography, Optical coherence tomography were done for all patients. 
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Focal Photocoaulation was done for focal leak at peri and parafoveal area 
signifying macular edema. Direct treatment of leaking microanuerysms, were 
carried out with 50 to 100µ spot size of Nd Yag  laser for 0.05 to 0.1 sec to produce 
mild to moderate burns. 
Grid pattern photocoagulation was done for diffuse leak with 50 to 100µ spot 
size for 0.05 to 0.1 sec. Modified grid (Both focal and grid laser) were done for 
patients with  mixed type of maculopathy. Ischemic maculopathy associated with 
ischemia elsewhere in fundus were given scatter photocoagulation and kept under 
observation. 
 Patients with Cystoid macular edema in OCT and refractory diffuse DME 
unresponsive to focal/diffuse laser photocoagulation were treated with intravitreal 
injection of Triamcinolone acetonide (4 mg/0.1 ml). Pre& post treatment follow up 
was done with OCT  to find the treatment response. Patients with Vitreomacular 
traction (VMT) and Taut posterior hyaloid (TPH) patterns in OCT were planned for 
vitrectomy. 
INTRAVITREAL injections procedure:  
Injection procedure guidelines include consideration of  pre existing 
conditions such as active external infection, eyelid abnormalities, povidone iodine, 
lid scrubs, preinjection topical antibiotics, lid speculum, drape, gloves, topical 
anaesthesia and post injection topical antibiotics. The risk of endophthalmitis 
following intravitreal injection is estimated to be approximately < 0.1%. 
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Guidelines for intravitreal injection: 
Draping the ocular surface, eye lid, and eye lashes with povidone iodine, 
usage of lid speculum  and avoidance of  contamination of the needle with eye lid 
margin. Pupil should be dilated, topical anaesthetic drops should be applied before 
injection. Intraocular pressure(IOP) should be checked following injection. 
FOLLOW UP: 
Patients were followed up  after  4 th,8 th & 16 th week, following laser 
photocoagulation. Following intravitreal injection patients were followed up on the 
immediate day following injection. They were followed up every week for 1 month, 
then every 2 weeks subsequently upto 6 months. 
Main outcome measures: 
 1 .Best corrected visual acuity before & after treatment(Snellen’s chart) 
.  2. Macular thickness by OCT. 
 3.  IOP should be measured by Goldmann ‘s applanation tonometry.                                            
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OBSERVATION AND ANALYSIS 
 
1. AGE DISTRIBUTION 
                                               Table 1 
Age group(years) No of patients Percentage 
21 - 30 2 4% 
31 - 40 6 12% 
41 - 50 19 38% 
51 - 60 12 24% 
61 - 70 9 18% 
71 - 80 2 4% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our study the predominant age group affected is the  41-50 years range 38% 
followed by 51-60 years range 24% and 61-70  years range 18%. In our study 60% 
of cases are aged between 41-60.This correlates with the Wisconsin Epidemiological 
study 5of Diabetic  Retinopathy revealed diabetic retinopathy more prevalent in the 
middle  aged population affecting people aged 41-60 years. 
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2. SEX DISTRIBUTION 
 
Table 2 
 
Sex No. of Cases Percentage 
Male 27 54% 
Female 23 46% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our study, males were predominantly affected (54%) which correlated 
with  the Wisconsin Epidemiological Study  Of Diabetic retinopathy which showed 
a  male to female ratio of  1.5:1. 
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3. DURATION OF DM  
Table 3 
Duration No of patients with 
DME 
Percentage of DME 
<5 yrs 12 24% 
5-10 yrs 22 44% 
10-20yrs 16 32% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. In our study though the incidence of DME with duration of <5yrs was 24% 
2. The incidence was 44% in patients with duration of 5-10 yrs 
3. And the incidence of DME with duration of 10-20 yrs was 32% 
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4. FFA TYPES 
Table 4 
Type No. of Cases Total 
Focal 18 25 43 
Diffuse 17 12 29 
Mixed 7 9 16 
Ischemic 8 4 12 
                                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our study 43 patients had  focal type , 29 had diffuse,  16 had mixed type of 
maculopathy and 12 had ischemic maculopathy. 
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5.  OCT TYPES 
 
Table 5 
  
Type No of cases Total 
Spongy type 20 24 44 
Cystoid type 9 6 15 
Cystoid with serous RD 8 11 19 
Spongy with serous RD 10 8 18 
Vitreomacular 
traction(VMT) 
2 1 3 
Taut posterior 
hyaloid(TPH) 
1 0 1 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
In our study 44 patients had spongy type in OCT, 15 had cystoid type,19 had  serous 
retinal detachment with cystoid pattern, 18 had serous RD . VMT was  seen in 3 
patients and TPH in 1 patient.  This correlated with the study done by Anush goyal 
et al which  was presented in AIOC.24 
53 
 
6. TREATMENT 
Table 6 
LASER PHOTOCOAGULATION 48 
IVTA 34 
 
 Laser photocoagulation was done in 48 patients. IVTA was given to  
34 patients. 14 patients with ischemic maculopathy were kept under observation   
4  patients with VMT and TPH patterns in OCT were planned for vitrectomy. But  
2 patients were lost to follow up and 2 patients were not willing for surgery. 
 
7. RESULTS of treatment in DME 
Visual acuity on presentation 
Table 7 
Visual acuity          RE           LE Total no of pts 
        <2/60             3             2           5 
      4/60-6/60           15           17          32 
     6/36-6/18           19           21          40 
       <6/12           13           10          23 
 
40 patients had visusl acuity ranging from6/36-6/18 and 23 patients had  
visual acuity between <6/12. 48 patients were treated with laser  photocoagulation & 
34 were given injection IVTA. 18 patients with ischemic  maculopathy were kept 
under observation . All patients were followed up over a  period of 6 months. 
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8. Pretreatment visual acuity (Before laser & IVTA) 
 
                                                Table 8 
 
Visual acuity RE LE Total no of     patients 
<2/60 0 1 1 
4/60  -   6/60 13 14 27 
6/60   -   6/18 16 18 34 
<6/12 9 20 20 
 
 
 
9. Post treatment visual acuity (After laser & IVTA) 
 
Table 9 
 
Visual acuity RE LE Total no of patients 
          <2/60            2             0           2 
      4/60-6/60           10            12          22 
      6/36-6/18           23            16          21 
         <6/12           16            21          37 
 
Post treatment only 2 patients had visual acuity less than2/60. 37 patients  
had visual acuity less than 6/12. 21 patients had VA ranging  
from 6/36-6/18 which correlated with the study by Becker et al.25 
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COMPARISON  BETWEEN  PRE  AND  POST  TREATMENT  VISUAL 
 ACUITY 
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The post treatment visual acuity showed an increase with 37 patients  having a  VA 
of  <   6 / 12 compared to 20% in the same range before  treatment.  Chi square test 
showed p value< 0.02 on comparing the pre and post  treatment visual acuity which 
is significant. 
10. Pre treatment IOP 
                                                          Table 10 
                 IOP (mmHg)                  No of patients 
                 10-12                 7 
                 11-13               15 
                 14-16               10     
                 17-19                2 
                   >20                0 
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11.  Post treatment IOP 
                                                           Table 11 
IOP(mmHg) No of patients 
10-12 4 
11-13 16 
14-16 8 
17-19 3 
>20 3 
 
Most patients maintained their IOP within the normal range with 2-4 mmHg  
between the pre and post treatment . But 3 patients had IOP >20 mmHg who were 
treated with topical 0.5% Timolol eye drops. Their IOP normalised at the end of 6 
months. 
 
29. Effect of laser photocoagulation on visual acuity(VA) after 6 months 
                                                   Table 12 
Visual acuity after 4 
months 
No of patients % of visual loss 
Improved 31 64.5 
Unchanged 12 25 
Worsened 5 10.41 
 
Following  laser photocoagulation vision improved in 64.5%worsened,  
in 10.% which   correlated with the study conducted by E G  Danes et al, 
R G Petty et ea, E M Kohner et al.26 
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13. Effect of IVTA on VA after 6 months 
                                             Table 13 
VA after 4 months No of patients % of visual loss 
Improved 22 64.70 
Unchanged 10 29.41 
Worsened 2 5.88 
 
Following IVTA vision improved in 64.70%, unchanged in 
29%,worsened in  5%.  Majority of the patients improved after IVTA 
injection which correlated  with AmJ Ophthalmol 2005:140(4):695-
702.27 
 
V/A after 6 months of laser photocoagulation 
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 V/A after 6 months of  IVTA 
 
 
 
 
 
 
 
 
 
 
 
14. PRE TREATMENT MACULAR THICKNESS(Before laser 
photocoagulation) 
                                                        Table 14 
Macular 
thickness(µm) 
        RE             LE Total no of pts 
200-400            15            10              25 
400-600              4              8            12 
600-800              6              3              9 
800-1000              2              0              2 
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15. POST TREATMENT MACULAR THICKNESS(Following laser 
photocoagulation) 
                                                  Table 15 
Macular 
thickness 
         RE             LE   Total no of pts 
        <200            15            20           31 
    200-400             10              9           10 
    400-600               4              6            5 
    600-800               0              2              2 
 
 Pre treatment macular thickness was between 200-1000µ. 10patients 
had macular thickness between 200-400µ. Following laser treatment 
majority of  patients had macular thickness less than 200µ which 
correlated with the ETDRS  study.9 
 
COMPARISON BETWEEN PRE AND POST TREATMENT 
MACULAR  THICKNESS FOLLOWING LASER 
 
 
 
 
 
 
 
 
 
Chi square test showed a p value <0.04% on comparing the pre and 
post treatment macular thickness which was significant. 
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16. Macular thickness in OCT pre & post treatment in FOCAL 
MACULOPATHY: 
 
Table 16 
 
Treatment Decreased Unchanged Increased 
laser 29 2 0 
IVTA 11 1 0 
 
 
17. Macular thickness in OCT pre & post treatment in DIFFUSE 
MACULOPATHY: 
 
Table 17 
 
Treatment Decreased Unchanged Increased 
Laser 9 0 1 
IVTA 14 1 1 
 
18. Macular thickness in OCT pre & post treatment in MIXED  
MACULOPATHY: 
 
                                            Table 18 
 
 Decreased Unchanged Increased 
laser 2 1 0 
IVTA 11 0 0 
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19. Macular thickness in OCT pre & post treatment in  
ISCHEMIC MACULOPATHY: 
                                        Table 19 
Treatment Decreased Unchanged Increased 
observation 3 1 8 
 
Macular thickness in OCT pre & post treatment in focal, diffuse 
and mixed  maculopathy 
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Majority of the  cases showed a decresease in macular thickness after  
treatment which was documented in OCT. 
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20.  Macular thickness in OCT pre & post treatment in SPONGY 
EDEMA  
                                       TABLE 20 
Treatment Decreased Unchanged Increased 
laser 33 3 8 
 
21. Macular thickness in OCT pre & post treatment in CYSTOID 
EDEMA 
                                               Table 21 
Treatment Decreased Unchanged Increased 
IVTA 14 1 0 
 
22. Macular thickness in OCT pre & post treatment in CYSTOID 
EDEMA  with SEROUS RD 
                                                 Table 22 
Treatment Decreased Unchanged Increased 
IVTA 18 0 1 
 
23. Macular thickness in OCT pre & post treatment in SPONGY 
EDEMA  with SEROUS RD 
                                                Table 23 
Treatment Decreased Unchanged Increased 
laser 15 1 2 
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24. Macular thickness in OCT pre & post treatment in VMT 
 
                                           Table 24 
Treatment Decreased Unchanged Increased 
Observation(not willing for 
surgery) 
0 0 2 
 
Macular thickness in OCT pre & post treatment 
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Majority of the cases showed a decrease in macular thickness after 
treatment with laser / Inj IVTA. 
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25. Pre treatment macular thickness before IVTA 
Table 25 
Macular thickness RE LE Total no 
200-400 µ 6 4 10 
400-600µ 10 5 15 
600-800µ 4 3 7 
800-1000µ 2 0 2 
 
26. Post treatment macular thickness after IVTA 
Table 26 
Macular thickness RE LE Total no 
<200µ 9 11 20 
200 - 400µ 7 4 11 
400 - 600µ 2 0 2 
600-800µ 0 1 1 
 
The pre treatment macular thickness was between 200 to 1000µ. 10 patients had  
macular thickness between 200-400µ. 24  patients had macular thickness    between 
400 to1000µ. Post treatment all patients had macular thickness less  than 600µ 
except one patient.  20 patients had reduced thickness <200µ which  correlated with 
the study published in Br J Ophthalmol 2004, 88(9):1131-6.28 
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Comparison between pre and post treatment macular thickness after IVTA 
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Chi square test showed a p value,0.02 on comparing the pre and post  reatment 
macular thickness after IVTA which was significant. 
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CASE 1 
 
 
 
 
 
 
 
Fig. 13 OCT of the LE line scan showing spongy type of macular edema. 
Central  macular thickness was 480µ 
 
 
 
 
 
 
 
 
Fig 14. OCT  LE after 24 weeks after laser treatment showing a reduction in 
the macular thickness to275µ 
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CASE 2 
 
 
 
 
 
 
 
Fig 15. OCT RE line scan showed spongy edema with serous RD with central 
macular  thickmess of 275µ 
 
 
 
 
 
 
 
 
Fig. 16 OCT RE showed resolution of the serous RD with central macular 
thickness of 208µ after laser treatment 
 
 
 
68 
 
 
CASE 3 
  
 
 
 
 
 
 
Fig. 17 OCT  RE line scan showed cystoid type of macular edema with central 
macular thickness of 603µ    
 
 
 
 
 
 
 
 
Fig 18 OCT RE line scan shows reduction in th ecystoid spaces with central 
macular thickness reduced to 260µ after injection IVTA 
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DISCUSSION 
 Diabetic macular edema is the major cause of visual morbidity in diabetic 
patients. The laser treatment given by ETDRS remains the standard therapy of 
DME. Focal and diffuse types of leaks diagnosed on FFA were treated with focal 
and grid laser. Cystoid type and recalcitrant type of macular edema not responding 
to laser treatment were given injection IVTA. 
1  In our study 27 patients were below 50 yrs and 23 patients were above 50 
years. This correlates with the Wisconsin Epidemiological study5 of Diabetic 
Retinopathy  and revealed diabetic retinopathy more prevalent in the middle 
aged population affecting people aged 41-60 years. 
2.  Males were predominantly affected around 54% which correlated with the 
Wisconsin Epidemiological Study5 which showed a male to female ratio of 
1.5:1. 
3. 24% of patients had DME with 5 years duration, 44% with duration of  5-10 
years, & 32% with duration of 10-20 years. 
4.  In FFA, 43 patients had focal type, 29 patients had diffuse type, 12 had 
ischemic type and 16 patients had mixed type of maculopathy. 
5.  In OCT classification 44 patients had spongy type, 15 patients had cystoid 
type, 19 patients had cystoid with serous RD, 18 patients had  spongy with 
serous RD, 3  patients had VMT and 1 had TPH. This correlated with the 
study done by Anush goyal et al which  was presented in AIOC24 
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6. 48 pts were treated with laser photocoagulation and 34 pts were treated with 
IVTA. 
7.  Only 2 patients had visual acuity < 2/60 and 37 patients had visual acuity  
 < 6/12. which correlated with the study by Becker et al.25  Chi  square  test  
showed p value  < 0.02 on comparing the pre and post treatment visual 
acuity which is significant. 
8.  After laser treatment 10 patients had macular thickness between 200- 400 µ 
and majority had macular thickness <200µ which correlated with the ETDRS 
study.9  Chi  square  test  showed  a p value  < 0.04% on comparing the pre 
and post treatment macular thickness which was significant. 
9. Following IVTA 20 patients had macular thickness less than 200µ  and all  
patients had macular thickness less than 600µ which correlated with the 
study published in Br J Ophthalmol 2004, 88(9):1131-6.28  
Chi square test showed a p value, 0.02 on comparing the pre and post 
treatment macular thickness after IVTA which was significant.  
10.  Following laser photocoagulation VA improved in 64%, worsened in 25%,  
unchanged in 10 %. which   correlated with the study conducted by E.G  
Danes et al, R G Petty et ea, E M Kohner et al.26  
11.  Following IVTA , VA improved in 64%, unchaned in 29%, worsened in  
5%. which correlated with AmJ Ophthalmol 2005:140(4):695-702.27  
12.  Patients with ischemic maculopathy  in FFA and VMT & TPH in OCT  had  
the worst visual prognosis and their macular thickness was increased over 
the period of study.  
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CONCLUSION 
 In our hospital 100 eyes of 50 patients were studied  during  NOVEMBER 
2009 to NOVEMBER 2011. The incidence of  diabetic  maculopathy is found to be 
commoner in the middle age group of 40-60 years   the majority were males and the 
incidence of diabetic maculopathy increased  with the increase in duration of 
diabetes. 
 Among the FFA patterns focal leaks were commoner and  in OCT spongy 
edema were the common types. Patients who had ischemic type  of maculopathy 
were  kept under observation and had the worst prognosis over time. The majority of 
focal leaks improved with focal laser, and diffuse  leaks with grid laser. And 
majority of recalcitrant types of macular edema and cystoid  type showed 
improvement with IVTA injection. Patients with ischemic  maculopathy  in FFA and 
VMT & TPH in OCT  had the worst visual prognosis 
The  overall improvement in visual acuity and the reduction in the macular 
thickness was detected and  documented by OCT.  FFA helped in detecting the 
specific leakage  patterns and  to decide the type of laser treatment. OCT aids in 
detecting  subtle  macular edema that may be difficult to detect on slit lamp 
biomicroscopy and in documenting the treatment response. and monitoring the 
response to treatment more accurately and less invasively than FFA. OCT & FFA 
play a major and complementary role in the diabetic maculopathy management and 
follow up. 
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PROFORMA 
 
Serial No 
Name 
Age 
Sex 
OP No. 
Occupation 
History 
a. Complaints (RE/LE) 
i. Defective vision 
ii. Pain in the eye 
iii. Field defects 
 
Past history: 
i. Diabetes 
Type 
Duration 
On oral hypoglycemics/inj insulin 
ii. Hypertension 
     Duration 
     Medication 
77 
Family history 
Systemic examination: 
              Pulse rate  
              Blood pressure 
              RBS 
              Urine alb & sugar 
Ocular examination: 
RE                                    LE 
Visual acuity   -                    
Conjunctiva    - 
Cornea    - 
Anterior chamber   - 
Iris     - 
Pupils     - 
Lens     - 
Tension(applanation tonometer) - 
Fields by Tangent screen  - 
Colour vision(Ishihara ‘s chart)  -            
Fundus examination  - 
By Direct Ophthalmoscopy 
By Indirect Ophthalmoscopy 
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Fundus fluorescein angiography    : Type of leak 
Optical coherence tomography      : Macular thickness 
Tretment: 
Laser photocoagulation: 
Type (Focal/Diffuse/Modified Grid) 
Power 
Spot size 
Number of burns 
Injection IVTA: 
Date 
Follow up: 
Visual acuity 
Macular thickness 
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KEY TO MASTER CHRART 
VA   - Visual acuity 
NPDR   - Non proliferative diabetic retinopathy 
CSME   -    Clinically significant macular edema 
FFA      -   Fundus fluorescein angiography 
OCT     - Optical coherence tomography 
RE        - Right eye 
LE        - Left eye 
IVTA     - Intravitreal Triamcinolone acetonide 
VMT     - Vitreomacular traction 
TPH       - Taut posterior hyaloid 
CME     - Cystoid macular edema 
     
 
 
 
